Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: glycerol; purified water; sodium hydroxide; sorbitol solution (70 per cent) (non-crystallising); methyl hydroxybenzoate; ethanol; propyl hydroxybenzoate; sunset yellow fcf; quinoline yellow; flavour - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.hypertension. oral lasix may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with lasix alone.

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa. a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium topical suspension usp, 10% is indicated in the topical treatment of acne vulgaris . sulfacetamide sodium topical suspension usp, 10% is contraindicated for use by patients having a known hypersensitivity to sulfonamides or any other component of this preparation (see warnings section).

United States - English - NLM (National Library of Medicine)

rosemar labs, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 98 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

rosemar labs, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 98 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

bi-coastal pharma international llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 98 mg in 1 g - indications: sodium sulfacetamide 9.8% and sulfur 4.8% cleanser is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications: sodium sulfacetamide 9.8% and sulfur 4.8% cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 9.8% and sulfur 4.8% cleanser is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

rosemar labs, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 98 mg in 1 g - this product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. this product is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

bi-coastal pharma international llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 90 mg in 1 g - sulfacetamide sodium and sulfur wash is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. sulfacetamide sodium and sulfur wash is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sulfacetamide sodium and sulfur wash is not to be used by patients with kidney disease.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus  (viridans group), haemophilus influenzae, klebsiella  species, and enterobacter  species. topically applied sulfonamides do not provide adequate coverage against neisseria  species, serratia marcescens  and pseudomonas aeruginosa . a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution usp, 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.